1 / 31

The Role of Differentiation Factors in Cancer Diseases

The Role of Differentiation Factors in Cancer Diseases. Pier Mario Biava Istituto di Ricovero e Cura a Carattere Scientifico Multimedica Milano. MOLECULAR WEIGHT OF DIFFERENT PROTEINS PRESENT IN ZEBRAFISH EMBRYO DURING GASTRULATION PERIOD. 1) 37% molecular weight of about 97KDa

bissonnette
Download Presentation

The Role of Differentiation Factors in Cancer Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Role of Differentiation Factors in Cancer Diseases Pier Mario Biava Istituto di Ricovero e Cura a Carattere Scientifico Multimedica Milano

  2. MOLECULAR WEIGHT OF DIFFERENT PROTEINS PRESENT IN ZEBRAFISH EMBRYO DURING GASTRULATION PERIOD 1) 37% molecular weight of about 97KDa 2) 14.6% molecular weight of about 45 KDa 3+4) 27.4% molecular weight of about 30-25 KDa 5) 4% molecular weight of about 20 KDa 6+7) 14% molecular weight of about 14 KDa

  3. Continues

  4. Lewis Lung Carcinoma Primary Tumor Growth in C57BL6 Mice

  5. Spiral CT during the arterial phase prior to treatment withstem cell differentiation stage factors(SCDSF) shows an advanced HCC of the right lobe. Neoplastic hypervascularized areas are present in segment 7, and a hypervascularized thrombus (arrow) occupies the right portal branch and reaches the main trunk.

  6. In the same patient, power doppler confirms the thrombosis inside the main portal vein (asterisk)

  7. Spiral CT performed 6 months after treatment with SCDSF shows the shrinkage of portal thrombus and disappearance of HCC in the right lobe

  8. Power doppler confirms the shrinkage of the thrombosis and the patency of the main portal vein

  9. In another case, CT during arterial phase prior to treatment with SCDSF shows several nodules of HCC

  10. CT performed 6 months after treatment with SCDSF shows the disappearance of neoplastic hypervascularization inside the nodules

  11. Treatment with stem cell differentiation stage factors of intermediate-advanced HCC: an open randomized clinical trial. 100 80 60 Survival (%) 40 20 Objective response & stable disease Progression 0 0 6 12 18 24 30 36 Months Livraghi T, Meloni F, Frosi A et al. Oncol Res 2005

  12. Caco2 cell growth.

  13. Histogram of quantification of Bax, Bcl-2, Bcl-xL and ratio Bax/Bcl-xL

  14. Caspase- activity in Caco-2 cells treated for 24 hrs, determined by a colorimetric assay kit (Chemicon)

  15. 1. Remove as much cancer burden as possible in all stages 1. Remove as much cancer burden as possible in all stages. 2. Epigenetic factors ( Differentiation Factors) should be used in an attempt to reprogram the cancer cells. 3. When radical surgery is impossible or not recommended, an ablative therapy should be considered. 4. In case of ablative therapies, and also in association with Stem Cell Differentiation Factors, the addition of small dosages of 5-FU and/or Cy should be considered, so as to trigger a DC-mediated immunostimulation; Ablin R. J.; Biava:P.M et al. Current Medicinal Chemistry, VOLUME: 21 ISSUE: 9 Year: 2014Page: [1082 - 1092]Pages: 11

More Related